News from our lab #Financing

Evosciences has agreed to finance most of BioMAdvanced Diagnostics laboratory equipment. It enables our start-up to benefit from state-of-the-art equipment while freeing up the cash which would have been necessary for such an investment.

“Even though our seed funding has been significant and our start-up is backed up by key players, it is paramount for us to preserve the funds we have raised to ensure the advancement of the product’s development process.” Frédéric Pette, BioMAdvanced Diagnostics CEO.

The collaboration between Evosciences and our start-up was built thanks to the Evosciences Biotech and young companies lease line program qualified for the French research tax credit (CIR).

Evosciences is a French company with more than thirty years of experience in the management of scientific assets. Present in Europe (Germany, Benelux, France, Great Britain, Scandinavian countries, Italy, Spain, Portugal, Switzerland) and also in the United States. Evosciences brings independent consultants specializing in their fields of activity (PhD, Finance, Business developers) and international culture together. Evosciences’ main mission is to enable companies like BioMAdvanced Diagnostics to optimize the use of their scientific equipment through its funding and remarketing services.

About BioMAdvanced Diagnostics

BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.

BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System based on 20 years of academic translational research. Its main goal is to enable a truly personalized, preventive and predictive medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.

The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. Two key benefits of its solutions : minimally invasive solutions for the patient and very substantial cost reductions for the Health Systems.